Recently Added |View All
News
Roswell Park presentations include findings from KOMET-001 in AML, new insights on risk of organ rejection after ICI.
News
Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.
News
Clinical Trial Offers CAR T-Cell Therapy Targeting MUC16 for Recurrent/Refractory Ovarian Cancer
Roswell Park Comprehensive Cancer Center is one of only four sites in the U.S. and the only one in New York State offering a phase 1 clinical trial of an investigational cellular therapy strategy for the treatment of recurrent or refractory ...
News
Join Roswell Park Experts at ASCO
Nearly two dozen experts from Roswell Park Comprehensive Cancer Center will be attending this year’s American Society of Clinical Oncology conference in Chicago, May 30-June 3, and we’d like to invite you to meet them.
News
Prantesh Jain, MD, FACP, Assistant Professor of Oncology, Department of Medicine at Roswell Park Comprehensive Cancer Center, will share initial results of the study during the 2025 annual meeting of the American Association for Cancer ...
News
Can Vitamin A Supplementation Reduce the Incidence of Chronic GVHD After Allogeneic Transplant?
Research has shown that vitamin A, which helps regulate a variety of immune responses, may have the potential to reduce the incidence of chronic GVHD or limit its severity.
Video
Roswell Park Set to Open Several New Trials this Year for Innovative CAR T-Cell Therapies
CAR T-cell therapies are the future of cancer treatment and Roswell Park Comprehensive Cancer Center is preparing to open a number of new trials based on research originating here and in partnership with the industry.
News
Phase 3 clinical trial is underway, it will evaluate the potential of combining an investigational drug, the targeted therapy XL092 (brand name Zanzalintinib), with the FDA-approved immunotherapy nivolumab (brand name Opdivo).
Video
Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials
Renier Brentjens, MD, PhD, has spent most of his career pioneering research into the development and use of CAR T-cell therapies in the hopes of finding innovative and effective treatments for cancer.
This site is intended for healthcare professionals
Click your preferred app store below to download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED